Given the crucial importance of IL-10 in immune dysfunction and the capacity of IL-10 to synergize with inflammatory cytokines to enhance viral replication in HIV-1-positive patients, inhibition of Tat/TLR4-MD2 may represent in the long term an attractive therapeutic strategy. This evidence concerns the gene IL10 and immune system disorder.